Bellevue Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bellevue Group’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$49.9M	Buy	2,380,000 +2,377,420	+92,148%	+$53.5M	1.19%	28
2025 Q4	$59.3K	Buy	+2,580	New	+$84.8K	﹤0.01%	170
2025 Q1	–	Sell	-4,000	Closed	-$168K	–	162
2024 Q4	$168K	Hold	4,000	–	–	﹤0.01%	147
2024 Q3	$222K	Hold	4,000	–	–	﹤0.01%	144
2024 Q2	$164K	Buy	+4,000	New	+$171K	﹤0.01%	154
2022 Q3	–	Sell	-31,000	Closed	-$1.85M	–	183
2022 Q2	$1.85M	Buy	31,000 +5,300	+21%	+$326K	0.03%	131
2022 Q1	$1.87M	Buy	25,700 +4,700	+22%	+$327K	0.02%	137
2021 Q4	$1.77M	Sell	21,000 -6,900	-25%	-$561K	0.02%	148
2021 Q3	$2.52M	Buy	27,900 +6,500	+30%	+$588K	0.03%	143
2021 Q2	$2.04M	Sell	21,400 -19,600	-48%	-$2.04M	0.02%	142
2021 Q1	$4.67M	Hold	41,000	–	–	0.05%	132
2020 Q4	$5.68M	Hold	41,000	–	–	0.07%	123
2020 Q3	$3.37M	Buy	41,000 +17,000	+71%	+$1.41M	0.05%	133
2020 Q2	$1.88M	Buy	24,000 +2,500	+12%	+$165K	0.03%	137
2020 Q1	$955K	Buy	+21,500	New	+$1.12M	0.02%	142
2019 Q3	–	Sell	-22,800	Closed	-$1.45M	–	219
2019 Q2	$1.45M	Sell	22,800 -7,000	-23%	-$446K	0.02%	137
2019 Q1	$2.07M	Buy	29,800 +7,600	+34%	+$434K	0.11%	107
2018 Q4	$965K	Sell	22,200 -9,650	-30%	-$527K	0.06%	117
2018 Q3	$2.43M	Sell	31,850 -7,300	-19%	-$594K	0.15%	100
2018 Q2	$3.01M	Sell	39,150 -1,150	-3%	-$74.3K	0.26%	75
2018 Q1	$2.06M	Sell	40,300 -600	-1%	-$30.2K	0.2%	78
2017 Q4	$1.9M	Sell	40,900 -1,100	-3%	-$53.9K	0.2%	80
2017 Q3	$2.24M	Hold	42,000	–	–	0.23%	78
2017 Q2	$1.61M	Hold	42,000	–	–	0.19%	89
2017 Q1	$2.85M	Sell	42,000 -1,000	-2%	-$76.2K	0.38%	66
2016 Q4	$3.02M	Hold	43,000	–	–	0.62%	46
2016 Q3	$3.05M	Buy	43,000 +15,000	+54%	+$957K	0.55%	54
2016 Q2	$1.37M	Buy	28,000 +18,000	+180%	+$1.16M	0.26%	88
2016 Q1	$633K	Buy	+10,000	New	+$654K	0.11%	106

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bellevue Group's RARE Position: Q1 2026 in Review

Bellevue Group increased its Ultragenyx Pharmaceutical (RARE) stake by 92,148% in Q1 2026, buying an estimated $53.5M and bringing the position to 2,380,000 shares worth $49.9M. The position accounts for 1.19% of the portfolio, ranked #28.

Bellevue Group first reported a position in RARE in Q1 2016 and has held it in 29 quarters since. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Bellevue Group held 2,380,000 shares of Ultragenyx Pharmaceutical worth $49.9M as of Q1 2026.
Bellevue Group bought 2,377,420 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $53.5M.
Ultragenyx Pharmaceutical made up 1.19% of Bellevue Group's portfolio in Q1 2026, its #28 holding.
Bellevue Group first reported a position in Ultragenyx Pharmaceutical in Q1 2016 and has held it in 29 quarters since.
296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.